

ASX Announcement 28 August 2020

## New North American and Expanded Asia Pacific Distribution Activities for the FIVE2 (ViewnVivo) Pre-Clinical Device

## Highlights

- OptiScan establishes new North America Distributor Arrangements
- Plans to establish new Asia Pacific Distribution Arrangements

OptiScan Imaging Limited (ASX: OIL) ('the Company' or 'OptiScan') is pleased to advise that it has altered its North American distribution arrangements. It has entered into an agreement with Advanced Microscopy Consultancy Services Inc ('AMCS') to provide technical, marketing and sales services to the Company in the United States and Canada. AMCS possesses significant pre-clinical microscopy and imaging expertise as well as multiple contacts in the research community.

The Company also advises that it has ended the Distribution Agreement with Scintica Instrumentation Inc ('Scintica') although it continues to explore potential opportunities to work with Scintica.

These changes to the Company's marketing and distribution activities in North America follow the Company's recent engagement of Dr Joseph Jiafu as a consultant to assist the Company to establish distribution arrangements in Japan, Korea, Singapore and other APAC countries (excluding China). Dr Jiafu is a microscopy expert and the former Asia Pacific In Vivo product leader for PerkinElmer Inc.

Executive Chair and CEO of OptiScan, Darren Lurie, said "We are excited to build upon our recent sales in the China market by adding highly qualified and experienced people to develop sales and distribution opportunities in North America and Asia. In addition, we have been able to enhance the technical, microscopy and pre-clinical application knowledge within the Company which will benefit us in all markets."

- ends -

This announcement has been authorised for release by the Board of OIL.

For investor queries, please contact: Darren Lurie Executive Chairman – Optiscan Imaging Limited E: <u>dlurie@optiscan.com</u>

## **About Optiscan**

Optiscan is an Australian company that has developed and patented miniaturised confocal microscopes, and is a global leader in the development and application of microscopic imaging and related technologies for medical and research markets.

## Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate", "believe", "could", "estimate", "expect", "future", "intend", "may", "opportunity", "plan", "potential", "project", "seek", "will" and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.